Scilex Holding Co (SCLX)

$1.92

-0.03

(-1.54%)

Market is closed - opens 7 PM, 19 Jul 2024

Performance

  • $1.88
    $2.00
    $1.92
    downward going graph

    2.12%

    Downside

    Day's Volatility :5.92%

    Upside

    3.88%

    downward going graph
  • $0.73
    $6.55
    $1.92
    downward going graph

    61.9%

    Downside

    52 Weeks Volatility :88.83%

    Upside

    70.69%

    downward going graph

Returns

PeriodScilex Holding CoIndex (Russel 2000)
3 Months
113.86%
0.0%
6 Months
28.86%
0.0%
1 Year
-68.73%
0.0%
3 Years
-79.47%
-17.0%

Highlights

Market Capitalization
236.2M
Book Value
- $1.79
Earnings Per Share (EPS)
-1.3
Wall Street Target Price
5.33
Profit Margin
-229.47%
Operating Margin TTM
-242.27%
Return On Assets TTM
-74.97%
Return On Equity TTM
0.0%
Revenue TTM
47.0M
Revenue Per Share TTM
0.39
Quarterly Revenue Growth YOY
2.9000000000000004%
Gross Profit TTM
27.2M
EBITDA
-102.2M
Diluted Eps TTM
-1.3
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.74
EPS Estimate Next Year
-0.49
EPS Estimate Current Quarter
-0.1
EPS Estimate Next Quarter
-0.16

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Scilex Holding Co(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 177.6%

Current $1.92
Target $5.33

Company Financials

FY19Y/Y Change
Revenue
21.0M
-
Net Income
-178.6M
-
Net Profit Margin
-849.11%
-
FY20Y/Y Change
Revenue
23.6M
↑ 12.01%
Net Income
-47.5M
↓ 73.39%
Net Profit Margin
-201.69%
↑ 647.42%
FY21Y/Y Change
Revenue
31.3M
↑ 32.92%
Net Income
-88.4M
↑ 86.08%
Net Profit Margin
-282.35%
↓ 80.66%
FY22Y/Y Change
Revenue
38.0M
↑ 21.45%
Net Income
-23.4M
↓ 73.58%
Net Profit Margin
-61.43%
↑ 220.92%
FY23Y/Y Change
Revenue
46.7M
↑ 22.9%
Net Income
-114.3M
↑ 389.35%
Net Profit Margin
-244.59%
↓ 183.16%
Q4 FY22Q/Q Change
Revenue
11.9M
↑ 4.76%
Net Income
-17.9M
↓ 183.18%
Net Profit Margin
-150.05%
↓ 339.04%
Q1 FY23Q/Q Change
Revenue
10.6M
↓ 11.22%
Net Income
-30.8M
↑ 71.96%
Net Profit Margin
-290.62%
↓ 140.57%
Q2 FY23Q/Q Change
Revenue
12.6M
↑ 18.9%
Net Income
-26.6M
↓ 13.35%
Net Profit Margin
-211.8%
↑ 78.82%
Q3 FY23Q/Q Change
Revenue
10.1M
↓ 19.59%
Net Income
-35.5M
↑ 33.32%
Net Profit Margin
-351.18%
↓ 139.38%
Q4 FY23Q/Q Change
Revenue
13.5M
↑ 33.06%
Net Income
-21.4M
↓ 39.77%
Net Profit Margin
-158.97%
↑ 192.21%
Q1 FY24Q/Q Change
Revenue
10.9M
↓ 19.15%
Net Income
-24.4M
↑ 13.91%
Net Profit Margin
-223.97%
↓ 65.0%
FY20Y/Y Change
Total Assets
81.5M
-
Total Liabilities
223.2M
-
FY21Y/Y Change
Total Assets
77.9M
↓ 4.38%
Total Liabilities
301.8M
↑ 35.23%
FY22Y/Y Change
Total Assets
86.5M
↑ 11.03%
Total Liabilities
50.3M
↓ 83.34%
FY23Y/Y Change
Total Assets
101.3M
↑ 17.08%
Total Liabilities
274.2M
↑ 445.35%
Q4 FY22Q/Q Change
Total Assets
86.5M
↓ 2.53%
Total Liabilities
50.3M
↓ 84.19%
Q1 FY23Q/Q Change
Total Assets
86.1M
↓ 0.55%
Total Liabilities
75.0M
↑ 49.09%
Q2 FY23Q/Q Change
Total Assets
126.5M
↑ 46.96%
Total Liabilities
116.0M
↑ 54.78%
Q3 FY23Q/Q Change
Total Assets
80.5M
↓ 36.32%
Total Liabilities
243.2M
↑ 109.57%
Q4 FY23Q/Q Change
Total Assets
101.3M
↑ 25.81%
Total Liabilities
274.2M
↑ 12.77%
Q1 FY24Q/Q Change
Total Assets
91.2M
↓ 9.94%
Total Liabilities
281.0M
↑ 2.47%
FY19Y/Y Change
Operating Cash Flow
-60.4M
-
Investing Cash Flow
-17.6M
-
Financing Cash Flow
15.8M
-
FY20Y/Y Change
Operating Cash Flow
-31.5M
↓ 47.93%
Investing Cash Flow
-25.0K
↓ 99.86%
Financing Cash Flow
-19.2M
↓ 221.51%
FY21Y/Y Change
Operating Cash Flow
-28.7M
↓ 8.89%
Investing Cash Flow
-139.4M
↑ 557420.0%
Financing Cash Flow
28.2M
↓ 246.91%
FY22Y/Y Change
Operating Cash Flow
-21.3M
↓ 25.84%
Investing Cash Flow
-2.1M
↓ 98.52%
Financing Cash Flow
21.2M
↓ 24.83%
Q4 FY22Q/Q Change
Operating Cash Flow
-725.0K
↓ 128.62%
Investing Cash Flow
-40.8M
↓ 199.99%
Financing Cash Flow
426.0K
↓ 106.2%
Q1 FY23Q/Q Change
Operating Cash Flow
-7.7M
↑ 968.14%
Investing Cash Flow
-8.0K
↓ 99.98%
Financing Cash Flow
10.6M
↑ 2395.07%
Q2 FY23Q/Q Change
Operating Cash Flow
-13.5M
↑ 73.98%
Investing Cash Flow
-8.0K
↑ 0.0%
Financing Cash Flow
43.5M
↑ 309.62%

Technicals Summary

Sell

Neutral

Buy

Scilex Holding Co is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Scilex Holding Co
Scilex Holding Co
-2.04%
28.86%
-68.73%
-79.47%
-79.47%
Eli Lilly And Company
Eli Lilly And Company
-4.19%
35.05%
87.16%
262.56%
694.92%
Johnson & Johnson
Johnson & Johnson
5.17%
-3.87%
-2.09%
-6.87%
19.27%
Merck & Co. Inc.
Merck & Co. Inc.
-4.18%
4.51%
17.27%
61.26%
52.66%
Abbvie Inc
Abbvie Inc
-0.58%
3.87%
24.3%
48.28%
149.69%
Amgen Inc.
Amgen Inc.
6.8%
7.52%
42.63%
34.14%
85.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Scilex Holding Co
Scilex Holding Co
NA
NA
NA
-0.74
0.0
-0.75
NA
-1.79
Eli Lilly And Company
Eli Lilly And Company
138.88
138.88
1.43
13.76
0.51
0.13
0.01
14.23
Johnson & Johnson
Johnson & Johnson
23.91
23.91
0.89
10.01
0.24
0.08
0.03
28.57
Merck & Co. Inc.
Merck & Co. Inc.
141.45
141.45
0.1
8.14
0.05
0.1
0.02
15.94
Abbvie Inc
Abbvie Inc
52.01
52.01
0.45
10.75
0.56
0.08
0.04
4.54
Amgen Inc.
Amgen Inc.
47.82
47.82
2.39
19.46
0.73
0.05
0.03
9.36
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Scilex Holding Co
Scilex Holding Co
Buy
$236.2M
-79.47%
NA
-229.47%
Eli Lilly And Company
Eli Lilly And Company
Buy
$847.8B
694.92%
138.88
17.08%
Johnson & Johnson
Johnson & Johnson
Buy
$376.8B
19.27%
23.91
44.92%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$318.9B
52.66%
141.45
3.76%
Abbvie Inc
Abbvie Inc
Buy
$309.5B
149.69%
52.01
11.02%
Amgen Inc.
Amgen Inc.
Buy
$180.1B
85.53%
47.82
12.74%

Insights on Scilex Holding Co

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 13.46M → 10.88M (in $), with an average decrease of 19.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -21.4M → -24.37M (in $), with an average decrease of 13.9% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 87.2% return, outperforming this stock by 155.9%

Institutional Holdings

  • State Street Corporation

    6.12%
  • BlackRock Inc

    5.52%
  • Vanguard Group Inc

    3.29%
  • Millennium Management LLC

    0.88%
  • Geode Capital Management, LLC

    0.87%
  • Goldman Sachs Group Inc

    0.73%

Company Information

Organization
Scilex Holding Co
Employees
106
CEO
Dr. Henry H. Ji Ph.D.
Industry
Healthcare

FAQs